FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011392386> ?p ?o ?g. }

• W3011392386 endingPage "1109" @default.
• W3011392386 startingPage "1102" @default.
• W3011392386 abstract "Abstract 2-fluorofucose (2FF) inhibits protein and cellular fucosylation. Afucosylation of IgG antibodies enhances antibody-dependent cell-mediated cytotoxicity by modulating antibody affinity for FcγRIIIa, which can impact secondary T-cell activation. Immune responses toward most common solid tumors are dominated by a humoral immune response rather than the presence of tumor-infiltrating cytotoxic T cells. IgG antibodies directed against numerous tumor-associated proteins are found in the sera of both patients with breast cancer and transgenic mice bearing mammary cancer. We questioned whether 2FF would have antitumor activity in two genetically distinct transgenic models; TgMMTV-neu (luminal B) and C3(1)-Tag (basal) mammary cancer. 2FF treatment significantly improved overall survival. The TgMMTV-neu doubled survival time compared with controls [P &lt; 0.0001; HR, 7.04; 95% confidence interval (CI), 3.31–15.0], and survival was significantly improved in C3(1)-Tag (P = 0.0013; HR, 3.36; 95% CI, 1.58–7.14). 2FF treated mice, not controls, developed delayed-type hypersensitivity and T-cell responses specific for syngeneic tumor lysates (P &lt; 0.0001). Serum IgG from 2FF-treated mice enhanced tumor lysis more efficiently than control sera (P = 0.004). Administration of 2FF for prophylaxis, at two different doses, significantly delayed tumor onset in both TgMMTV-neu; 20 mmol/L (P = 0.0004; HR, 3.55; 95% CI, 1.60–7.88) and 50 mmol/L (P = 0.0002; HR: 3.89; 95% CI, 1.71–8.86) and C3(1)-Tag; 20 mmol/L (P = 0.0020; HR, 2.51; 95% CI, 1.22–5.18), and 50 mmol/L (P = 0.0012; HR, 3.36; 95% CI, 1.57–7.18). Mammary cancer was prevented in 33% of TgMMTV-neu and 26% of C3(1)-Tag. 2FF has potent antitumor effects in mammary cancer models. The agent shows preclinical efficacy for both cancer treatment and prevention." @default.
• W3011392386 created "2020-03-23" @default.
• W3011392386 creator A5006018197 @default.
• W3011392386 creator A5011719233 @default.
• W3011392386 creator A5029132704 @default.
• W3011392386 creator A5031952463 @default.
• W3011392386 creator A5039848435 @default.
• W3011392386 creator A5050287661 @default.
• W3011392386 creator A5060432567 @default.
• W3011392386 creator A5089318759 @default.
• W3011392386 date "2020-05-01" @default.
• W3011392386 modified "2023-09-30" @default.
• W3011392386 title "Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers" @default.
• W3011392386 cites W1559033760 @default.
• W3011392386 cites W1589766395 @default.
• W3011392386 cites W1831036856 @default.
• W3011392386 cites W1931518331 @default.
• W3011392386 cites W1982056508 @default.
• W3011392386 cites W2020740632 @default.
• W3011392386 cites W2023765040 @default.
• W3011392386 cites W2029850226 @default.
• W3011392386 cites W2039894516 @default.
• W3011392386 cites W2071782367 @default.
• W3011392386 cites W2077219444 @default.
• W3011392386 cites W2100236398 @default.
• W3011392386 cites W2102466421 @default.
• W3011392386 cites W2124427232 @default.
• W3011392386 cites W2135548733 @default.
• W3011392386 cites W2151157422 @default.
• W3011392386 cites W2157377956 @default.
• W3011392386 cites W2170679699 @default.
• W3011392386 cites W2301919500 @default.
• W3011392386 cites W2344015854 @default.
• W3011392386 cites W2466558384 @default.
• W3011392386 cites W2480742538 @default.
• W3011392386 cites W2564006575 @default.
• W3011392386 cites W2577498041 @default.
• W3011392386 cites W2796207838 @default.
• W3011392386 doi "https://doi.org/10.1158/1535-7163.mct-19-0500" @default.
• W3011392386 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32165557" @default.
• W3011392386 hasPublicationYear "2020" @default.
• W3011392386 type Work @default.
• W3011392386 sameAs 3011392386 @default.
• W3011392386 citedByCount "9" @default.
• W3011392386 countsByYear W30113923862021 @default.
• W3011392386 countsByYear W30113923862022 @default.
• W3011392386 countsByYear W30113923862023 @default.
• W3011392386 crossrefType "journal-article" @default.
• W3011392386 hasAuthorship W3011392386A5006018197 @default.
• W3011392386 hasAuthorship W3011392386A5011719233 @default.
• W3011392386 hasAuthorship W3011392386A5029132704 @default.
• W3011392386 hasAuthorship W3011392386A5031952463 @default.
• W3011392386 hasAuthorship W3011392386A5039848435 @default.
• W3011392386 hasAuthorship W3011392386A5050287661 @default.
• W3011392386 hasAuthorship W3011392386A5060432567 @default.
• W3011392386 hasAuthorship W3011392386A5089318759 @default.
• W3011392386 hasBestOaLocation W30113923862 @default.
• W3011392386 hasConcept C108625454 @default.
• W3011392386 hasConcept C121608353 @default.
• W3011392386 hasConcept C126322002 @default.
• W3011392386 hasConcept C153911025 @default.
• W3011392386 hasConcept C154317977 @default.
• W3011392386 hasConcept C159654299 @default.
• W3011392386 hasConcept C202751555 @default.
• W3011392386 hasConcept C203014093 @default.
• W3011392386 hasConcept C206212055 @default.
• W3011392386 hasConcept C2776187077 @default.
• W3011392386 hasConcept C2779212266 @default.
• W3011392386 hasConcept C502942594 @default.
• W3011392386 hasConcept C530470458 @default.
• W3011392386 hasConcept C55493867 @default.
• W3011392386 hasConcept C71924100 @default.
• W3011392386 hasConcept C86803240 @default.
• W3011392386 hasConcept C8891405 @default.
• W3011392386 hasConceptScore W3011392386C108625454 @default.
• W3011392386 hasConceptScore W3011392386C121608353 @default.
• W3011392386 hasConceptScore W3011392386C126322002 @default.
• W3011392386 hasConceptScore W3011392386C153911025 @default.
• W3011392386 hasConceptScore W3011392386C154317977 @default.
• W3011392386 hasConceptScore W3011392386C159654299 @default.
• W3011392386 hasConceptScore W3011392386C202751555 @default.
• W3011392386 hasConceptScore W3011392386C203014093 @default.
• W3011392386 hasConceptScore W3011392386C206212055 @default.
• W3011392386 hasConceptScore W3011392386C2776187077 @default.
• W3011392386 hasConceptScore W3011392386C2779212266 @default.
• W3011392386 hasConceptScore W3011392386C502942594 @default.
• W3011392386 hasConceptScore W3011392386C530470458 @default.
• W3011392386 hasConceptScore W3011392386C55493867 @default.
• W3011392386 hasConceptScore W3011392386C71924100 @default.
• W3011392386 hasConceptScore W3011392386C86803240 @default.
• W3011392386 hasConceptScore W3011392386C8891405 @default.
• W3011392386 hasFunder F4320311929 @default.
• W3011392386 hasIssue "5" @default.
• W3011392386 hasLocation W30113923861 @default.
• W3011392386 hasLocation W301139238610 @default.
• W3011392386 hasLocation W30113923862 @default.
• W3011392386 hasLocation W30113923863 @default.
• W3011392386 hasLocation W30113923864 @default.

• next